Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 377-389

  Sahin, Ayguen ^a,d   Vercamer, Chantal ^b   Kaminski, Annette ^a   Fuchs, Tanja ^a   Florin, Alexandra ^a   Hahne, Jens Claus ^a   Mattot, Virgine ^b   Poutier Manzanedo, Albin ^c   Pietsch, Torsten ^a   Fafeur, Véronique ^b   Wernert, Nicolas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b INSTITUT PASTEUR DE LILLE   (France)

^c INSTITUT DE BIOLOGIE DE LILLE   (France)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dominant negative mutant; Ets 1; Ets family; Glioma; Mmp 9; Suppression subtractive hybridization; Tumor growth

Indexed keywords

GELATINASE B; TRANSCRIPTION FACTOR ELF 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR FLI 1;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RAT;

ALLANTOIS; ANIMALS; BINDING SITES; CELL DIVISION; CELL LINE, TUMOR; CHICK EMBRYO; CHORION; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEIN C-ETS-1; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 64649107438     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000161     Document Type: Article

References (88)

1. Maher EA, Furnari FB, Bachoo RM, et al: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
2. Kondo Y, Hollingsworth EF and Kondo S: Molecular targeting for malignant gliomas (Review). Int J Ocol 24: 1101-1109, 2004.
3. Kanzawa T, Ito H, Kondo Y and Kondo S: Current and future gene therapy for malignant gliomas. J Biomed Biotechnol: 25-34, 2003.
4. Valter MM, Hugel A, Huang HJ, et al: Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res 59: 5608-5614, 1999.
5. Kitange G, Kishikawa M, Nakayama T, Naito S, Iseki M and Shibata S: Expression of the Ets-1 proto-oncogene correlates with malignant potential in human astrocytic tumors. Mod Pathol 12: 618-626, 1999.
6. Kitange G, Shibata S, Tokunaga Y, et al: Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab Invest 79: 407-416, 1999.
7. Fleischman LF, Holtzclaw L, Russell JT, Mavrothalassitis G and Fisher RJ: Ets-1 in astrocytes: expression and transmitter-evoked phosphorylation. Mol Cell Biol 15: 925-931, 1995.
8. Sahin A, Velten M, Pietsch T, et al: Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med 15: 771-776, 2005.
9. Wernert N, Gilles F, Fafeur V, et al: Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 54: 5683-5688, 1994.
10. Behrens P, Rothe M, Florin A, Wellmann A and Wernert N: Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med 8: 149-154, 2001.
11. Behrens P, Rothe M, Wellmann A, Krischler J and Wernert N: The Ets-1 transcription factor is up-regulated together with MMP-1 and MMP-9 in the stroma of pre-invasive breast cancer. J Pathol 194: 43-50, 2001.
12. Iwasaka C, Tanaka K, Abe M and Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 169: 522-531, 1996.
13. Wasylyk C, Gutman A, Nicholson R and Wasylyk B: The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 10: 1127-1134, 1991.
14. Gouon V, Tucker GC, Kraus-Berthier L, Atassi G and Kieffer N: Up-regulated expression of the beta3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice. Int J Cancer 68: 650-662, 1996.
15. Hahne JC, Fuchs T, El Mustapha H, Okuducu AF, Bories JC and Wernert N: Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts. Int J Mol Med 18: 153-159, 2006.
16. Rothhammer T, Hahne JC, Florin A, et al: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 61: 118-128, 2004.
17. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F and Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene 6, 2005.
18. Forsyth PA and Roa WH: Primary central nervous system tumors in adults. Curr Treat Options Neurol 1: 377-394, 1999.
19. Choe G, Park JK, Jouben-Steele L, et al: Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8: 2894-2901, 2002.
20. Raithatha SA, Muzik H, Rewcastle NB, Johnston RN, Edwards DR and Forsyth PA: Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neurooncology 2: 145-150, 2000.
21. Rooprai HK, van Meter T, Rucklidge GJ, Hudson L, Everall IP and Pilkington GJ: Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours. Int J Oncol 13: 1153-1157, 1998.
22. Schultz C, Lemke N, Ge S, Golembieski WA and Rempel SA: Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62: 6270-6277, 2002.
23. Ohnishi T, Hiraga S, Izumoto S, Arita N, et al: Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis 16: 729-741, 1998.
24. Span PN, Manders P, Heuvel JJ, et al: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21: 8506-8509, 2002.
25. Fujimoto J, Aoki I, Toyoki H, Khatun S and Tamaya T: Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers. Ann Oncol 13: 1605-1611, 2002.
26. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G and Reich R: PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 9: 1412-1419, 2003.
27. Takai N, Miyazaki T, Nishida M, Nasu K and Miyakawa I: c-Ets1 is a promising marker in epithelial ovarian cancer. Int J Mol Med 9: 287-292, 2002.
28. Sasaki H, Yukiue H, Moiriyama S, et al: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 101: 242-247, 2001.
29. Pande P, Mathur M, Shukla NK and Ralhan R: Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J Pathol 189: 40-45, 1999.
30. Tokuhara K, Ogata Y, Nakagawa M and Shirouzu K: Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma. Int Surg 88: 25-33, 2003.
31. Delannoy-Courdent A, Mattot V, Fafeur V, et al: The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci 111: 1521-1534, 1998.
32. Mattot V, Vercamer C, Soncin F, et al: Constitutive expression of the DNA-binding domain of Ets1 increases endothelial cell adhesion and stimulates their organization into capillary-like structures. Oncogene 19: 762-772, 2000.
33. Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F and Vandenbunder B: Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 22: 1795-1806, 2003.
34. Markowitz D, Hesdorffer C, Ward M, Goff S and Bank A: Retroviral gene transfer using safe and efficient packaging cell lines. Ann NY Acad Sci 612: 407-414, 1990.
35. Gilles F, Raes MB, Stehelin D, Vandenbunder B and Fafeur V: The c-ets-1 proto-oncogene is a new early-response gene differentially regulated by cytokines and growth factors in human fibroblasts. Exp Cell Res 222: 370-378, 1996.
36. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J and Sato H: Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin alpha5 expression in U251 glioma cell line. Cancer Res 61: 7985-7991, 2001.
37. Albini A, Iwamoto Y, Kleinman HK, et al: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245, 1987.
38. Ribatti D, Vacca A, Roncali L and Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 40: 1189-1197, 1996.
39. Lakka SS, Gondi CS, Yanamandra N, et al: Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 63: 2454-2461, 2003.
40. Quandt K, Grote K and Werner T: GenomeInspector: a new approach to detect correlation patterns of elements on genomic sequences. Comput Appl Biosci 12: 405-413, 1996.
41. Wernert N, Raes MB, Lassalle P, et al: c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 140: 119-127, 1992.
42. Behrens P, Mathiak M, Mangold E, et al: Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 107: 183-188, 2003.
43. Nakano T, Abe M, Tanaka K, Shineha R, Satomi S and Sato Y: Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol 184: 255-262, 2000.
44. Sawka-Verhelle D, Escoubet-Lozach L, Fong AL, et al: PE-1/METS, an antiproliferative Ets repressor factor, is induced by CREB-1/CREM-1 during macrophage differentiation. J Biol Chem 279: 17772-17784, 2004.
45. Foulds CE, Nelson ML, Blaszczak AG and Graves BJ: Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 24: 10954-10964, 2004.
46. Albanese C, Johnson J, Watanabe G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-23597, 1995.
47. Bassuk AG and Leiden JM: The role of Ets transcription factors in the development and function of the mammalian immune system. Adv Immunol 64: 65-104, 1997.
48. Kopp JL, Wilder PJ, Desler M, et al: Unique and selective effects of five Ets family members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the promoter of the type II transforming growth factor-beta receptor gene. J Biol Chem 279: 19407-19420, 2004.
49. Pijuan-Thompson V and Gladson CL: Ligation of integrin alpha5beta1 is required for internalization of vitronectin by integrin alphavbeta3. J Biol Chem 272: 2736-2743, 1997.
50. Birkenmeier TM, McQuillan JJ, Boedeker ED, Argraves WS, Ruoslahti E and Dean DC: The alpha 5 beta 1 fibronectin receptor. Characterization of the alpha 5 gene promoter. J Biol Chem 266: 20544-20549, 1991.
51. Aplin AE, Short SM and Juliano RL: Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains. J Biol Chem 274: 31223-31228, 1999.
52. Renshaw MW, Ren XD and Schwartz MA: Growth factor activation of MAP kinase requires cell adhesion. EMBO J 16: 5592-5599, 1997.
53. Lelievre E, Lionneton F, Soncin F and Vandenbunder B: The Ets family contains transcriptional activators and repressors involved in angiogenesis. Int J Biochem Cell Biol 33: 391-407, 2001.
54. Takai N, Miyazaki T, Fujisawa K, Nasu K and Miyakawa I: Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer 89: 2059-2067, 2000.
55. Oikawa T and Yamada T: Molecular biology of the Ets family of transcription factors. Gene 303: 11-34, 2003.
56. Sato Y: Transcription factor ETS-1 as a molecular target for angiogenesis inhibition. Hum Cell 11: 207-214, 1998.
57. Chakraborti S, Mandal M, Das S, Mandal A and Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253: 269-285, 2003.
58. Sementchenko VI and Watson DK: Ets target genes: past, present and future. Oncogene 19: 6533-6548, 2000.
59. Rao RK, Shantaram M, Aroor AR, Raja A, Davis TP and Rao A: Molecular variants of epidermal growth factor in malignant astrocytoma. Peptides 17: 179-181, 1996.
60. Kondraganti S, Mohanam S, Chintala SK, et al: Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60: 6851-6855, 2000.
61. Nakamura Y, Esnault S, Maeda T, Kelly EA, Malter JS and Jarjour NN: Ets-1 regulates TNF-alpha-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts. J Immunol 172: 1945-1952, 2004.
62. Dittmer J, Vetter M, Blumenthal SG, Lindemann RK and Kolbl H: Importance of ets1 proto-oncogene for breast cancer progression. Zentralbl Gynakol 126: 269-271, 2004.
63. Esteve PO, Robledo O, Potworowski EF and St-Pierre Y: Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway. Biochem Biophys Res Commun 296: 864-869, 2002.
64. Bowers DC, Fan S, Walter KA, et al: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60: 4277-4283, 2000.
65. Murthy MS and Pande SV: A stress-regulated protein, GRP58, a member of thioredoxin superfamily, is a carnitine palmitoyltransferase isoenzyme. Biochem J 304: 31-34, 1994.
66. Sahlin L, Holmgren A and Eriksson H: Thioredoxin messenger ribonucleic acid is regulated by estradiol in the rat uterus. Biol Reprod 57: 1056-1059, 1997.
67. Cross RL and Muller V: The evolution of A-, F-, and V-type ATP synthases and ATPases: reversals in function and changes in the H+/ATP coupling ratio. FEBS Lett 576: 1-4, 2004.
68. Antes I, Chandler D, Wang H and Oster G: The unbinding of ATP from F1-ATPase. Biophys J 85: 695-706, 2003.
69. Goding JW, Grobben B and Slegers H: Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 1638: 1-19, 2003.
70. Dutta SK and Verma M: Isolation and characterization of nonneuronal enolase (NNE) from Neurospora crassa and comparison with neuron specific enolase isolated from neuroblastoma cell line NG108. Biochem Int 15: 223-234, 1987.
71. Miyajima H, Takahashi Y and Kaneko E: Characterization of the glycolysis in lactate dehydrogenase-A deficiency. Muscle Nerve 18: 874-878, 1995.
72. Bohnsack MT, Regener K, Schwappach B, et al: Exp5 exports eEF1A via tRNA from nuclei and synergizes with other transport pathways to confine translation to the cytoplasm. EMBO J 21: 6205-6215, 2002.
73. Kato MV, Sato H, Nagayoshi M and Ikawa Y: Upregulation of the elongation factor-1alpha gene by p53 in association with death of an erythroleukemic cell line. Blood 90: 1373-1378, 1997.
74. Kato MV: The mechanisms of death of an erythroleukemic cell line by p53: involvement of the microtubule and mitochondria. Leuk Lymphoma 33: 181-186, 1999.
75. Chen E, Proestou G, Bourbeau D and Wang E: Rapid upregulation of peptide elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-induced apoptosis. Exp Cell Res 259: 140-148, 2000.
76. Duttaroy A, Bourbeau D, Wang XL and Wang E: Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res 238: 168-176, 1998.
77. Bergman BL, Scott RW, Bajpai A, Watts S and Baker JB: Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci USA 83: 996-1000, 1986.
78. Vadlamuri SV, Media J, Sankey SS, Nakeff A, Divine G and Rempel SA: SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions. Neurooncology 5: 244-254, 2003.
79. Rempel SA: Molecular biology of nervous system tumors. Hematol Oncol Clin North Am 15: 979-1006, 2001.
80. Meier R, Spreyer P, Ortmann R, Harel A and Monard D: Induction of glia-derived nexin after lesion of a peripheral nerve. Nature 342: 548-550, 1989.
81. Arcuri F, Papa S, Carducci A, et al: Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60: 130-140, 2004.
82. Bommer UA and Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36: 379-385, 2004.
83. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T and Bommer UA: The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci 112: 1257-1271, 1999.
84. Saadat M, Nakamura K, Mizuno Y, Kikuchi K and Yoshida MC: Regional localization of rat and mouse protein-tyrosine phosphatase PTP alpha/LRP gene (Ptpra) by fluorescence in situ hybridization. Jpn J Genet 70: 669-764, 1995.
85. Grumet M, Milev P, Sakurai T, et al: Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J Biol Chem 269: 12142-12146, 1994.
86. Milev P, Friedlander DR, Sakurai T, et al: Interactions of the chondroitin sulfate proteoglycan phosphacan, the extracellular domain of a receptor-type protein tyrosine phosphatase, with neurons, glia, and neural cell adhesion molecules. J Cell Biol 127: 1703-1715, 1994.
87. Storm SM and Khawaja XZ: Probing for drug-induced multiplex signal transduction pathways using high resolution two-dimensional gel electrophoresis: application to beta-adreno-ceptor stimulation in the rat C6 glioma cell. Brain Res Mol Brain Res 71: 50-60, 1999.
88. Chung EY, Shin SY and Lee YH: Amitriptyline induces early growth response-1 gene expression via ERK and JNK mitogen-activated protein kinase pathways in rat C6 glial cells. Neurosci Lett 422: 43-48, 2007.